{"id":23,"date":"2018-06-03T21:41:40","date_gmt":"2018-06-03T21:41:40","guid":{"rendered":"https:\/\/dorerconsulting.com\/dscc8\/?page_id=23"},"modified":"2022-11-23T22:10:35","modified_gmt":"2022-11-23T22:10:35","slug":"about","status":"publish","type":"page","link":"https:\/\/dorerconsulting.com\/dscc8\/about\/","title":{"rendered":"About"},"content":{"rendered":"<style>\nul.a {<br \/>\n    list-style-position: outside;<br \/>\n    padding-left: 20px;<br \/>\n}<br \/>\n<\/style>\n<h2><strong>David J. Dorer, Ph.D. <\/strong> has over twenty five years of experience as a Biostatistician in both industry and hospital based research.\u00a0\u00a0 His background includes work with clinical trials and observational studies.<\/h2>\n<h2><strong>Ariad Pharmaceuticals Experience<\/strong><\/h2>\n<ul class=\"a\">\n<li>\n<h3>Phase I, II, and III clinical trials:\u00a0\u00a0 Design and Analysis.<\/h3>\n<\/li>\n<li>\n<h3>Regulatory Filings for Drug Approval worldwide.<\/h3>\n<\/li>\n<li>\n<h3>Safety Regulatory Filings FDA, Europe, Japan &amp; Health Canada.<\/h3>\n<\/li>\n<li>\n<h3>Postmarketing Safety Filings.<\/h3>\n<\/li>\n<li>\n<h3>Two approved oncology compounds:\u00a0\u00a0 Brigatinib (Non-Small Cell Lung Cancer) &amp; Ponatinib (Chronic Myeloid Leukemia).<\/h3>\n<\/li>\n<li>\n<h3>Statistician member Safety Managment Teams.<\/h3>\n<\/li>\n<li>\n<h3>Statistician member Clinical Pharmacology Research Group.<\/h3>\n<\/li>\n<li>\n<h3>Coauthor:\u00a0 Publications, Posters &amp; Conference Presentations.<\/h3>\n<\/li>\n<\/ul>\n<h2><!-- &nbsp;\n\n\n<blockquote class=\"alignleft\"> --><br \/>\n<strong>Massachusetts General Hospital<\/strong><!--<\/blockquote>\n\n\n--><\/h2>\n<ul class=\"a\">\n<li>\n<h3>Phase III Clinical Trials:\u00a0\u00a0 Design and Analysis.<\/h3>\n<\/li>\n<li>\n<h3>Long Term Follow up Studies.<\/h3>\n<\/li>\n<li>\n<h3>Medical Fields: neurology, surgery, pediatrics, infectious disease, rehabilitation medicine, psychiatry, endocrinology and cardiology.<\/h3>\n<\/li>\n<li>\n<h3>Member Clinical Trial Data Safety Monitoring Committees.<\/h3>\n<\/li>\n<li>\n<h3>Example Methods:\u00a0\u00a0 Survival Analysis, Logistic Regression, Group Sequential Trials, Mixed Models.<\/h3>\n<\/li>\n<li>\n<h3>Biostatistician MGH Statistical Consulting Service.<\/h3>\n<\/li>\n<li>\n<h3>Instructor: Seminars for Physicians on Statistical Methods.<\/h3>\n<\/li>\n<li>\n<h3>Coauthor:\u00a0\u00a0 Grant Applications and Publications.<\/h3>\n<\/li>\n<li>\n<h3>Co-Investigator:\u00a0\u00a0 NIH Grants.<\/h3>\n<\/li>\n<\/ul>\n<h2><!--  &nbsp;\n--><br \/>\n<strong>Education<\/strong><\/h2>\n<ul class=\"a\">\n<li>\n<h3>Massachusetts Institute of Technology:\u00a0 Undergraduate and Graduate.<\/h3>\n<\/li>\n<li>\n<h3>Harvard University &amp; NASA Ames Research Center:\u00a0 Postdoctoral Research Fellow.<\/h3>\n<\/li>\n<\/ul>\n<p>v1.4<\/p>\n","protected":false},"excerpt":{"rendered":"<p>David J. Dorer, Ph.D. has over twenty five years of experience as a Biostatistician in both industry and hospital based research.\u00a0\u00a0 His background includes work with clinical trials and observational studies. Ariad Pharmaceuticals Experience Phase I, II, and III clinical trials:\u00a0\u00a0 Design and Analysis. Regulatory Filings for Drug Approval worldwide. Safety Regulatory Filings FDA, Europe, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/dorerconsulting.com\/dscc8\/about\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;About&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":20,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-23","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/dorerconsulting.com\/dscc8\/wp-json\/wp\/v2\/pages\/23","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dorerconsulting.com\/dscc8\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dorerconsulting.com\/dscc8\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dorerconsulting.com\/dscc8\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dorerconsulting.com\/dscc8\/wp-json\/wp\/v2\/comments?post=23"}],"version-history":[{"count":5,"href":"https:\/\/dorerconsulting.com\/dscc8\/wp-json\/wp\/v2\/pages\/23\/revisions"}],"predecessor-version":[{"id":536,"href":"https:\/\/dorerconsulting.com\/dscc8\/wp-json\/wp\/v2\/pages\/23\/revisions\/536"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dorerconsulting.com\/dscc8\/wp-json\/wp\/v2\/media\/20"}],"wp:attachment":[{"href":"https:\/\/dorerconsulting.com\/dscc8\/wp-json\/wp\/v2\/media?parent=23"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}